-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Tipifarnib in Natural Killer Cell Lymphomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tipifarnib in Natural Killer Cell Lymphomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tipifarnib in Natural Killer Cell Lymphomas Drug Details: Tipifarnib (Zarnestra)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sirolimus Albumin-bound in High-Grade Glioma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Sirolimus Albumin-bound in High-Grade Glioma Drug Details: Sirolimus protein-bound particles for injectable suspension (Fyarro) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMS-986360 in Metastatic Renal Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BMS-986360 in Metastatic Renal Cell Carcinoma Drug Details: BMS-986360 (CC-90001) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Retifanlimab in Metastatic Adenocarcinoma of The Pancreas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Retifanlimab in Metastatic Adenocarcinoma of The Pancreas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Retifanlimab in Metastatic Adenocarcinoma of The Pancreas Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CPI-100 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CPI-100 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CPI-100 in Solid Tumor Drug Details: CPI-100 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NCP-112 in Atopic Dermatitis (Atopic Eczema)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NCP-112 in Atopic Dermatitis (Atopic Eczema) Drug Details: NCP-112 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cenerimod in Systemic Lupus Erythematosus
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Cenerimod in Systemic Lupus Erythematosus Drug Details:Cenerimod (ACT-334441) is under development for the treatment of systemic...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CPI-100
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry CPI-100 Drug Details CPI-100 is under development for the treatment of solid tumor. The...